CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Walls, Gerard M., Oughton, Jamie B., Chalmers, Anthony J., Brown, Sarah, Collinson, Fiona, Forster, Martin D., Franks, Kevin N., Gilbert, Alexandra, Hanna, Gerard G., Hannaway, Nicola, Harrow, Stephen, Haswell, Tom, Hiley, Crispin T., Hinsley, Samantha, Krebs, Matthew, Murden, Geraldine, Phillip, Rachel, Ryan, Anderson J., Salem, Ahmed, Sebag-Montefoire, David, Shaw, Paul, Twelves, Chris J., Walker, Katrina, Young, Robin J., Faivre-Finn, Corinne, Greystoke, Alastair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548952/
https://www.ncbi.nlm.nih.gov/pubmed/33072895
http://dx.doi.org/10.1016/j.ctro.2020.09.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548952/
https://www.ncbi.nlm.nih.gov/pubmed/33072895
http://dx.doi.org/10.1016/j.ctro.2020.09.006

Ejemplares similares